Source 1primary paper2025MED
Toolkit/pharmacologic modulation of splicing regulators
pharmacologic modulation of splicing regulators
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Emerging therapeutic strategies aim to counteract these processes through antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete method used to build, optimize, or evolve an engineered system.
Mechanisms
pharmacologic modulation of splicing regulator activitysplicing correction via altered exon selectionTarget processes
recombinationselectionsignalingValidation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Aberrant activity of splicing regulators disrupts canonical exon selection, leading to altered receptor signaling or secretion of soluble decoy isoforms that evade immune recognition.
Emerging strategies to counteract splicing-mediated resistance include antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Understanding splicing-driven antigenic plasticity provides a framework for RNA-informed precision antibody therapies designed to restore antigen expression, overcome immune escape, and enhance durable clinical responses.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug pharmacologic-modulation-of-splicing-regulators
Emerging therapeutic strategies aim to counteract these processes through antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Source:
mechanismsupports
Aberrant activity of splicing regulators disrupts canonical exon selection, leading to altered receptor signaling or secretion of soluble decoy isoforms that evade immune recognition.
Source:
therapeutic strategysupports
Emerging strategies to counteract splicing-mediated resistance include antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Source:
translational frameworksupports
Understanding splicing-driven antigenic plasticity provides a framework for RNA-informed precision antibody therapies designed to restore antigen expression, overcome immune escape, and enhance durable clinical responses.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.